Cytotoxic drug-induced lung injury

Linda S Snyder, Marshall I. Hertz

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Cytotoxic drug-induced pulmonary disease is a major cause of morbidity and mortality in immunocompromised patients. It is estimated that 20% of all patients receiving cytotoxic drugs will develop a symptomatic pulmonary reaction. Therefore, the possibility of a toxic drug reaction must be considered in all patients developing pulmonary disease during or following treatment with these agents. Clinical manifestations of lung toxicity are nonspecific and parallel the signs and symptoms of diffuse lung infection and malignant disease in the chest. For this reason, the diagnosis of cytotoxic drug-induced lung damage is one of exclusion of the various opportunistic infections that afflict this patient population. This typically requires careful microbiologic studies of bronchoalveolar lavage (BAL) samples and lung tissue. The diagnosis of cytotoxic drug-induced lung injury is often vexing. In the future, (BAL) may assume a more prominent diagnostic role and suggest insights into the pathogenesis of this entity.

Original languageEnglish (US)
Pages (from-to)217-228
Number of pages12
JournalSeminars in Respiratory Infections
Volume3
Issue number3
StatePublished - Sep 1988
Externally publishedYes

Fingerprint

Lung Injury
Lung
Pharmaceutical Preparations
Bronchoalveolar Lavage
Lung Diseases
Poisons
Opportunistic Infections
Immunocompromised Host
Signs and Symptoms
Thorax
Morbidity
Mortality
Infection
Population

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Microbiology (medical)

Cite this

Cytotoxic drug-induced lung injury. / Snyder, Linda S; Hertz, Marshall I.

In: Seminars in Respiratory Infections, Vol. 3, No. 3, 09.1988, p. 217-228.

Research output: Contribution to journalArticle

Snyder, LS & Hertz, MI 1988, 'Cytotoxic drug-induced lung injury', Seminars in Respiratory Infections, vol. 3, no. 3, pp. 217-228.
Snyder, Linda S ; Hertz, Marshall I. / Cytotoxic drug-induced lung injury. In: Seminars in Respiratory Infections. 1988 ; Vol. 3, No. 3. pp. 217-228.
@article{18ec7e7dcbad4ae8b58ccd8e93c2c18f,
title = "Cytotoxic drug-induced lung injury",
abstract = "Cytotoxic drug-induced pulmonary disease is a major cause of morbidity and mortality in immunocompromised patients. It is estimated that 20{\%} of all patients receiving cytotoxic drugs will develop a symptomatic pulmonary reaction. Therefore, the possibility of a toxic drug reaction must be considered in all patients developing pulmonary disease during or following treatment with these agents. Clinical manifestations of lung toxicity are nonspecific and parallel the signs and symptoms of diffuse lung infection and malignant disease in the chest. For this reason, the diagnosis of cytotoxic drug-induced lung damage is one of exclusion of the various opportunistic infections that afflict this patient population. This typically requires careful microbiologic studies of bronchoalveolar lavage (BAL) samples and lung tissue. The diagnosis of cytotoxic drug-induced lung injury is often vexing. In the future, (BAL) may assume a more prominent diagnostic role and suggest insights into the pathogenesis of this entity.",
author = "Snyder, {Linda S} and Hertz, {Marshall I.}",
year = "1988",
month = "9",
language = "English (US)",
volume = "3",
pages = "217--228",
journal = "Seminars in Respiratory Infections",
issn = "0882-0546",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Cytotoxic drug-induced lung injury

AU - Snyder, Linda S

AU - Hertz, Marshall I.

PY - 1988/9

Y1 - 1988/9

N2 - Cytotoxic drug-induced pulmonary disease is a major cause of morbidity and mortality in immunocompromised patients. It is estimated that 20% of all patients receiving cytotoxic drugs will develop a symptomatic pulmonary reaction. Therefore, the possibility of a toxic drug reaction must be considered in all patients developing pulmonary disease during or following treatment with these agents. Clinical manifestations of lung toxicity are nonspecific and parallel the signs and symptoms of diffuse lung infection and malignant disease in the chest. For this reason, the diagnosis of cytotoxic drug-induced lung damage is one of exclusion of the various opportunistic infections that afflict this patient population. This typically requires careful microbiologic studies of bronchoalveolar lavage (BAL) samples and lung tissue. The diagnosis of cytotoxic drug-induced lung injury is often vexing. In the future, (BAL) may assume a more prominent diagnostic role and suggest insights into the pathogenesis of this entity.

AB - Cytotoxic drug-induced pulmonary disease is a major cause of morbidity and mortality in immunocompromised patients. It is estimated that 20% of all patients receiving cytotoxic drugs will develop a symptomatic pulmonary reaction. Therefore, the possibility of a toxic drug reaction must be considered in all patients developing pulmonary disease during or following treatment with these agents. Clinical manifestations of lung toxicity are nonspecific and parallel the signs and symptoms of diffuse lung infection and malignant disease in the chest. For this reason, the diagnosis of cytotoxic drug-induced lung damage is one of exclusion of the various opportunistic infections that afflict this patient population. This typically requires careful microbiologic studies of bronchoalveolar lavage (BAL) samples and lung tissue. The diagnosis of cytotoxic drug-induced lung injury is often vexing. In the future, (BAL) may assume a more prominent diagnostic role and suggest insights into the pathogenesis of this entity.

UR - http://www.scopus.com/inward/record.url?scp=0024078321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024078321&partnerID=8YFLogxK

M3 - Article

C2 - 3055113

AN - SCOPUS:0024078321

VL - 3

SP - 217

EP - 228

JO - Seminars in Respiratory Infections

JF - Seminars in Respiratory Infections

SN - 0882-0546

IS - 3

ER -